Investors

“SynAct Pharma is at an incredible inflection point with clinical study data from both the EXPAND and RESOLVE studies due in the second half of this year. Our platform of molecules with the lead AP1189 has the opportunity to transform the way we treat inflammatory diseases such as rheumatoid arthritis. I’m eager to work with the management team and board to prepare the company for potential partners and shareholders for the next phase of growth.”